Your browser is no longer supported. Please, upgrade your browser.
Settings
ACIU AC Immune SA daily Stock Chart
ACIU [NASD]
AC Immune SA
Index- P/E17.50 EPS (ttm)0.32 Insider Own51.67% Shs Outstand70.02M Perf Week3.70%
Market Cap392.11M Forward P/E- EPS next Y-0.88 Insider Trans0.00% Shs Float32.65M Perf Month-3.28%
Income24.50M PEG- EPS next Q-0.22 Inst Own27.40% Short Float1.88% Perf Quarter18.64%
Sales81.60M P/S4.81 EPS this Y-78.10% Inst Trans-0.16% Short Ratio5.28 Perf Half Y-49.91%
Book/sh3.60 P/B1.56 EPS next Y-225.00% ROA11.70% Target Price10.54 Perf Year-52.46%
Cash/sh4.36 P/C1.28 EPS next 5Y- ROE13.70% 52W Range3.25 - 17.40 Perf YTD-40.74%
Dividend- P/FCF11.43 EPS past 5Y-31.60% ROI-27.80% 52W High-67.82% Beta-
Dividend %- Quick Ratio5.10 Sales past 5Y-3.60% Gross Margin- 52W Low72.31% ATR0.31
Employees104 Current Ratio5.10 Sales Q/Q5046.90% Oper. Margin27.00% RSI (14)54.03 Volatility6.67% 5.16%
OptionableNo Debt/Eq0.20 EPS Q/Q562.70% Profit Margin30.00% Rel Volume0.47 Prev Close5.48
ShortableYes LT Debt/Eq0.01 EarningsAug 14 BMO Payout0.00% Avg Volume116.39K Price5.60
Recom1.70 SMA202.89% SMA505.43% SMA200-18.53% Volume55,072 Change2.19%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Jul-18-19 10:26AM  AC Immune Initiates Phase I Study for Alzheimer's Disease Zacks -6.96%
Jul-17-19 07:00AM  AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer, an Investigational Treatment for Alzheimers Disease GlobeNewswire +5.56%
Jul-11-19 08:00AM  AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimers Disease-like Symptoms in Subjects with Down Syndrome GlobeNewswire
Jul-10-19 10:52AM  Introducing AC Immune (NASDAQ:ACIU), The Stock That Slid 66% In The Last Year Simply Wall St.
Jun-29-19 06:07PM  Heres What Hedge Funds Think About AC Immune SA (ACIU) Insider Monkey
Jun-28-19 08:36AM  AC Immune Announces Election of New Chairman of the Board at Annual General Meeting GlobeNewswire
Jun-27-19 07:00AM  AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimers in Down Syndrome GlobeNewswire
Jun-20-19 07:00AM  AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimers Disease GlobeNewswire
May-15-19 08:35AM  AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates Zacks
07:36AM  AC Immune: 1Q Earnings Snapshot Associated Press
07:00AM  AC Immune Reports Q1 2019 Financial Results and Business Update GlobeNewswire
May-08-19 01:27PM  Heres What Hedge Funds Think About AC Immune SA (ACIU) Insider Monkey
Apr-24-19 10:33AM  AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
Apr-09-19 07:02AM  What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own? Simply Wall St.
Apr-03-19 09:58AM  Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003 Zacks
Apr-01-19 07:00AM  AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-29-19 02:00AM  AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD Conference GlobeNewswire
Mar-27-19 10:48AM  Lilly (LLY) Signs New Immunology Deal With Private Biotech Zacks
07:00AM  New Clinical Data on AC Immunes Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD Conference GlobeNewswire
Mar-26-19 09:00AM  What Makes AC Immune (ACIU) a New Buy Stock Zacks
Mar-21-19 07:00AM  AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-04-19 09:59AM  AC Immune to Report Progress of Early-Stage Pipeline at AD/PD Congress GlobeNewswire
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +9.98%
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
07:00AM  AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimers Disease GlobeNewswire
Feb-07-19 07:00AM  AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development GlobeNewswire
Feb-06-19 09:10AM  What Makes AC Immune (ACIU) a New Buy Stock Zacks
Feb-01-19 08:37AM  AC Immune Enters Oversold Territory Zacks
Jan-30-19 04:47PM  Roche Halts Two Late-Stage Studies on Alzheimer's Candidate Zacks -65.98%
04:42PM  Roche Scraps Alzheimer's Test But Investors Punished This Stock Investor's Business Daily
11:41AM  Roche, AC Immune drop Alzheimer drug trials after setback Reuters
10:16AM  Why AC Immune SA Is Imploding Motley Fool
09:49AM  Genentech kills big drug study in early Alzheimer's patients American City Business Journals
01:36AM  Roche drops Alzheimer drug trials after setback Reuters
01:00AM  AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimers Disease GlobeNewswire
Jan-25-19 10:30AM  Top Ranked Momentum Stocks to Buy for January 25th Zacks +5.44%
Jan-23-19 10:01AM  Top Ranked Momentum Stocks to Buy for January 23rd Zacks -5.36%
Jan-22-19 06:42AM  Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-17-19 06:56AM  Moving Average Crossover Alert: AC Immune Zacks
Jan-16-19 09:01AM  Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher Zacks
Jan-07-19 03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
Jan-03-19 04:00AM  AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer GlobeNewswire -7.73%
Dec-19-18 07:16AM  WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership PR Newswire -7.92%
06:31AM  AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership GlobeNewswire
Dec-13-18 09:00AM  Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug Zacks +5.41%
Dec-12-18 07:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:31AM  AC Immune and Lilly Announce License and Collaboration Agreement GlobeNewswire
06:10AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:00AM  Lilly and AC Immune Announce License and Collaboration Agreement PR Newswire
Dec-07-18 04:16PM  In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away GlobeNewswire
Dec-06-18 09:42AM  What You Must Know About AC Immune SAs (NASDAQ:ACIU) Beta Value Simply Wall St.
Nov-30-18 05:37AM  AC Immune (ACIU) Shares March Higher, Can It Continue? Zacks
Nov-15-18 04:01AM  AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease GlobeNewswire +9.16%
Nov-13-18 07:30AM  AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01AM  AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-12-18 04:01AM  AC Immune to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-09-18 04:01AM  AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Nov-05-18 10:30AM  Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline Zacks
Nov-01-18 06:01AM  AC Immune to Present at 2018 Society for Neurosciences Meeting GlobeNewswire +5.31%
05:01AM  AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Oct-29-18 06:01AM  AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620 GlobeNewswire -5.74%
05:00AM  AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy GlobeNewswire
Oct-25-18 04:00AM  AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona GlobeNewswire -7.79%
Oct-22-18 04:01AM  AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence GlobeNewswire -5.50%
Oct-17-18 08:35AM  Investor Expectations to Drive Momentum within Matthews International, AC Immune SA, Entercom Communications, Sunrun, Axcelis Technologies, and Advanced Disposal Services Discovering Underlying Factors of Influence GlobeNewswire
Aug-22-18 08:15AM  Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-20-18 04:01AM  AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome GlobeNewswire
Aug-08-18 07:30AM  AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01AM  AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-31-18 04:06PM  AC Immune Announces Successful Closing of Second Subscription Rights Offering GlobeNewswire
Jul-25-18 05:55PM  New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target GlobeNewswire
Jul-23-18 08:31PM  AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 02:04PM  Here's Why AC Immune SA Rose as Much as 21.6% Today Motley Fool +21.48%
Jul-18-18 07:17PM  AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares GlobeNewswire
Jul-17-18 04:09PM  AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares GlobeNewswire
04:01AM  Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago GlobeNewswire
Jul-06-18 07:19AM  AC Immune Announces Results of Annual General Meeting GlobeNewswire +38.28%
Jun-08-18 07:55AM  Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics N.V., BRF S.A., and National Steel with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-02-18 06:50PM  What Does AC Immune SAs (NASDAQ:ACIU) Ownership Structure Look Like? Simply Wall St.
08:43AM  Moving Average Crossover Alert: AC Immune SA (ACIU) Zacks
04:00AM  AC Immune Reports First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Apr-27-18 04:31PM  AC Immune Announces Results of Extraordinary Shareholders Meeting GlobeNewswire
Apr-20-18 03:54PM  Will AC Immune SAs (NASDAQ:ACIU) Earnings Grow Over The Next Few Years? Simply Wall St.
Apr-05-18 04:01AM  AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease GlobeNewswire -11.11%
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE +12.49%
Mar-27-18 08:30AM  Investor Expectations to Drive Momentum within Ambev S.A, AC Immune SA, Comp En De Mn Cemig ADS, GSV Capital, Novartis AG, and New York Discovering Underlying Factors of Influence GlobeNewswire
Mar-23-18 11:59AM  AC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse Benzinga -9.12%
Mar-20-18 05:21PM  AC Immune posts 4Q profit Associated Press
05:00AM  AC Immune reports full-year 2017 financial results - successful first year as a public company GlobeNewswire
Mar-15-18 05:00AM  AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease GlobeNewswire
Feb-06-18 08:31AM  AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference GlobeNewswire
Dec-27-17 08:37AM  AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-18-17 05:25PM  AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017 Simply Wall St.
Dec-01-17 02:20PM  AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire
Nov-28-17 07:50AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 28, 2017 Capital Cube
Nov-24-17 12:25PM  AC Immune SA (ACIU): Financial Strength Analysis Simply Wall St.
Nov-21-17 08:32AM  AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire +13.11%
Nov-16-17 12:25PM  AC Immune SA Value Analysis (NASDAQ:ACIU) : November 16, 2017 Capital Cube
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.